In the latest quarter, 6 analysts provided ratings for Vir Biotechnology (NASDAQ:VIR), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing ...
In the preceding three months, 6 analysts have released ratings for Vir Biotechnology (NASDAQ:VIR), presenting a wide array of perspectives from bullish to bearish. The following table summarizes ...
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the second quarter ended June ...
Hosted on MSN
Raymond James Initiates Coverage of Vir Biotechnology (VIR) with Outperform Recommendation
Fintel reports that on July 11, 2025, Raymond James initiated coverage of Vir Biotechnology (NasdaqGS:VIR) with a Outperform recommendation. Analyst Price Forecast Suggests 232.11% Upside As of June ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results